Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Donald J Kyle

Showing results (21-30 of 25) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 25 results.
The Journal of Clinical Investigation|October 26, 2023
The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomniaGarth T Whiteside, Donald J Kyle, Ram P Kapil, et al.
Pharmacology & Therapeutics|January 14, 2020
Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysisAndras Garami, Yury P Shimansky, Zoltan Rumbus, et al.
Current Medicinal Chemistry|June 2, 2026
Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor LigandsDonald J Kyle, Naoki Tsuno, Laykea Tafesse, et al.
Journal of Medicinal Chemistry|July 25, 2014
Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain managementLaykea Tafesse, Toshiyuki Kanemasa, Noriyuki Kurose, et al.
Pulmonary Pharmacology & Therapeutics|April 3, 2003
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294Donna D Gale, Peter Hofer, Domenico Spina, et al.
Pageof 3

Showing results (21-30 of 25) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 25 results.
The Journal of Clinical Investigation|October 26, 2023
The nociceptin/orphanin FQ receptor partial agonist sunobinop promotes non-REM sleep in rodents and patients with insomniaGarth T Whiteside, Donald J Kyle, Ram P Kapil, et al.
Pharmacology & Therapeutics|January 14, 2020
Hyperthermia induced by transient receptor potential vanilloid-1 (TRPV1) antagonists in human clinical trials: Insights from mathematical modeling and meta-analysisAndras Garami, Yury P Shimansky, Zoltan Rumbus, et al.
Current Medicinal Chemistry|June 2, 2026
Design, Synthesis, and Pharmacological Characterization of Substituted Quinoxalines as NOP Receptor LigandsDonald J Kyle, Naoki Tsuno, Laykea Tafesse, et al.
Journal of Medicinal Chemistry|July 25, 2014
Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain managementLaykea Tafesse, Toshiyuki Kanemasa, Noriyuki Kurose, et al.
Pulmonary Pharmacology & Therapeutics|April 3, 2003
Pharmacology of a new cyclic nucleotide phosphodiesterase type 4 inhibitor, V11294Donna D Gale, Peter Hofer, Domenico Spina, et al.
Pageof 3